Zimberelimab: all 51 studies that test it

Page 1 of 1. Open to participants first (21), then studies with results posted, then the rest; newest registration first within each.

• Futibatinib (TAS-120) in Patients With Advanced Biliary Tract CancerRecruitingNCT07710885Phase 3
• Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCCRecruitingNCT07397611Phase 2
• Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)Not yet recruitingNCT07337447Phase 2
• Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder CancerNot yet recruitingNCT06528483Phase 2
• Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.RecruitingNCT06431633Phase 3
• Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain MetastasesRecruitingNCT06238921Phase 1/2
• Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic CancerNot yet recruitingNCT06166589Phase 2
• A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical CancerRecruitingNCT06155396Phase 2
• Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer.Not yet recruitingNCT06128460Phase 2
• Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT06107114Phase 2
• Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACCRecruitingNCT06055738Phase 2
• SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)Not yet recruitingNCT06009029Phase 2
• Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung CancerNot yet recruitingNCT05978401Phase 1/2
• Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate CancerRecruitingNCT05915442Phase 2
• Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid TumorsRecruitingNCT05909436Phase 1/2
• A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's LymphomaRecruitingNCT05900765Phase 2
• Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)RecruitingNCT05872724Phase 2
• A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical CancerRecruitingNCT05798819Phase 3
• Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic AdenocarcinomaRecruitingNCT05688215Phase 1/2
• GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)Not yet recruitingNCT05518318Phase 3
• A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.RecruitingNCT05024097Phase 2
• Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate CancerTerminatedNCT05177770Phase 2Results posted
• Study to Assess the Effects of GS-3583 in Participants With Advanced Solid TumorsTerminatedNCT04747470Phase 1Results posted
• Zimberelimab + Domvanalimab in Gastroesophageal AdenocarcinomaWithdrawnNCT07283848Phase 2
• Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBCWithdrawnNCT07134556Phase 2
• IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE CancersActive, not recruitingNCT06790706Phase 2
• PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder CancerActive, not recruitingNCT06133517Phase 2
• Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)Active, not recruitingNCT06048133Phase 2
• A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated LiposarcomaActive, not recruitingNCT05886634Phase 2
• Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical CancerActive, not recruitingNCT05824468Phase 2
• Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell CarcinomaStatus unknownNCT05759312Phase 1/2
• Domvanalimab and Zimberelimab in Advanced Liver CancersActive, not recruitingNCT05724563Phase 2
• Study of Novel Treatment Combinations in Patients With Lung CancerActive, not recruitingNCT05633667Phase 2
• A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the BodyCompletedNCT05568095Phase 3
• Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT05502237Phase 3
• Switch Maintenance in PancreaticSuspendedNCT05419479Phase 1/2
• A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial CarcinomaActive, not recruitingNCT05335941Phase 2
• Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory MelanomaActive, not recruitingNCT05130177Phase 2
• Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid TumorsActive, not recruitingNCT05007782Phase 1
• A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck CancersWithdrawnNCT04892875Phase 1
• Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung CancerActive, not recruitingNCT04791839Phase 2
• A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced MalignanciesCompletedNCT04772989Phase 1
• Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerCompletedNCT04736173Phase 2
• AB154 Combined With AB122 for Recurrent GlioblastomaActive, not recruitingNCT04656535Early Phase 1
• Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid TumorsCompletedNCT04087018Phase 1
• Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical CancerStatus unknownNCT03972722Phase 2
• A Study to Evaluate Immunotherapy Combinations in Participants With Lung CancerCompletedNCT03846310Phase 1
• Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid TumorsCompletedNCT03713905Phase 1
• Study of GLS-010 Injection in the Treatment of Classical Hodgkin's LymphomaStatus unknownNCT03655483Phase 2
• A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced MalignanciesCompletedNCT03629756Phase 1
• Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadActive, not recruitingNCT03547973Phase 2

← Zimberelimab overview